PT907379E - Agentes de contraste bioactivados para imagiologia de diagnostico - Google Patents

Agentes de contraste bioactivados para imagiologia de diagnostico

Info

Publication number
PT907379E
PT907379E PT97916974T PT97916974T PT907379E PT 907379 E PT907379 E PT 907379E PT 97916974 T PT97916974 T PT 97916974T PT 97916974 T PT97916974 T PT 97916974T PT 907379 E PT907379 E PT 907379E
Authority
PT
Portugal
Prior art keywords
agents
bioactivated
diagnostic
imagiology
relates
Prior art date
Application number
PT97916974T
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel M Scott
Randall B Lauffer
Thomas J Mcmurry
David J Parmelee
Stephane Dumas
Stephen O Dunham
Original Assignee
Epix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc filed Critical Epix Medical Inc
Publication of PT907379E publication Critical patent/PT907379E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT97916974T 1996-04-01 1997-03-25 Agentes de contraste bioactivados para imagiologia de diagnostico PT907379E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1444896P 1996-04-01 1996-04-01

Publications (1)

Publication Number Publication Date
PT907379E true PT907379E (pt) 2004-09-30

Family

ID=21765541

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97916974T PT907379E (pt) 1996-04-01 1997-03-25 Agentes de contraste bioactivados para imagiologia de diagnostico

Country Status (18)

Country Link
US (3) US6709646B2 (2)
EP (1) EP0907379B1 (2)
JP (2) JP2000507577A (2)
KR (1) KR20060025233A (2)
CN (1) CN1108824C (2)
AT (1) ATE268187T1 (2)
AU (1) AU726914B2 (2)
BR (1) BR9708470A (2)
CA (1) CA2247620A1 (2)
DE (1) DE69729380T2 (2)
DK (1) DK0907379T3 (2)
ES (1) ES2217408T3 (2)
IL (1) IL125895A (2)
IS (1) IS2059B (2)
NO (1) NO319674B1 (2)
NZ (1) NZ331629A (2)
PT (1) PT907379E (2)
WO (1) WO1997036619A2 (2)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US6770261B2 (en) 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6675035B1 (en) * 1997-06-20 2004-01-06 Imaging Diagnostic Systems, Inc. Phantom for optical and magnetic resonance imaging quality control
AU742438C (en) * 1997-10-02 2003-05-22 Lantheus Medical Imaging, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
CA2307332C (en) * 1997-10-27 2008-09-16 California Institute Of Technology Magnetic resonance imaging agents for the delivery of therapeutic agents
US6713046B1 (en) 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
EP1032430A2 (en) 1997-11-17 2000-09-06 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
IT1297034B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
IT1297035B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US6230586B1 (en) * 1999-05-21 2001-05-15 Chung-Hsi Chang Electric drive device for a bicycle
IL147854A0 (en) 1999-07-29 2002-08-14 Epix Medical Inc Multimeric compounds, contrast agents containing the same and diagnostic methods utilizing the same
WO2001052906A2 (en) * 2000-01-22 2001-07-26 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
WO2001082795A2 (en) * 2000-05-04 2001-11-08 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
WO2001089584A2 (en) * 2000-05-23 2001-11-29 Amersham Health As Contrast agents
US6748259B1 (en) 2000-06-15 2004-06-08 Spectros Corporation Optical imaging of induced signals in vivo under ambient light conditions
AU2001276956A1 (en) 2000-07-17 2002-01-30 California Institute Of Technology Macrocyclic mri contrast agents
AU2002211517A1 (en) 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
ES2398393T3 (es) 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
EP1539249B1 (en) * 2002-07-22 2008-07-09 Bracco Imaging S.p.A. Procedures of cellular labelling with paramagnetic complexes for mri applications
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US20050124008A1 (en) * 2003-12-05 2005-06-09 Kauvar Lawrence M. Homogeneous competition assays
NO20035683D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av prostatakreft
FR2868320B1 (fr) * 2004-03-31 2007-11-02 Centre Nat Rech Scient Cnrse Agent de contraste pour l'imagerie par resonance magnetique
AU2006223112B2 (en) * 2005-03-11 2011-12-01 Wake Forest University Health Sciences Production of tissue engineered heart valves
AU2006223063B2 (en) * 2005-03-11 2011-11-17 Wake Forest University Health Sciences Tissue engineered blood vessels
US20060204539A1 (en) * 2005-03-11 2006-09-14 Anthony Atala Electrospun cell matrices
WO2006099332A2 (en) 2005-03-11 2006-09-21 Wake Forest University Health Sciences Production of tissue engineered digits and limbs
US7531503B2 (en) * 2005-03-11 2009-05-12 Wake Forest University Health Sciences Cell scaffold matrices with incorporated therapeutic agents
US20060204445A1 (en) * 2005-03-11 2006-09-14 Anthony Atala Cell scaffold matrices with image contrast agents
EP1743658A1 (en) 2005-07-14 2007-01-17 Schering Aktiengesellschaft Optical imaging of rheumatoid arthritis
WO2007005491A1 (en) * 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
JP5377965B2 (ja) 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
US8034898B2 (en) * 2005-12-29 2011-10-11 Collagen Medical, LLC Methods of collagen imaging
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
WO2009054327A1 (ja) * 2007-10-22 2009-04-30 Osaka Foundation For Trade And Industry Ｍｒｉ用プローブ
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
CN102356087A (zh) 2009-03-19 2012-02-15 惠氏有限责任公司 [2-(8,9-二氧代-2,6-二氮杂双环[5.2.0]壬-1(7)-烯-2-基)乙基]膦酸及其前体的制备方法
JP2011026294A (ja) 2009-06-26 2011-02-10 Canon Inc 化合物
WO2011035140A1 (en) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of contrast moieties to the lungs
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN102188722A (zh) * 2010-03-18 2011-09-21 中国科学院福建物质结构研究所 一种含二价铁的磁共振成像造影剂
US8192429B2 (en) 2010-06-29 2012-06-05 Theravant, Inc. Abnormality eradication through resonance
JP6148233B2 (ja) 2011-07-11 2017-06-21 インディ モレキュラー，インコーポレイテッド Ａｋｔ特異的捕捉剤、組成物ならびにその使用および製造方法
CN104159616B (zh) 2012-03-08 2017-10-31 托门医学股份公司 在牙科应用中用于诊断炎性组织的口香糖
WO2013131994A2 (en) * 2012-03-08 2013-09-12 Thommen Medical Ag Coating for the diagnosis of inflammatory tissues in dental applications
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10092679B2 (en) 2013-10-18 2018-10-09 Wake Forest University Health Sciences Laminous vascular constructs combining cell sheet engineering and electrospinning technologies
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
WO2015196208A2 (en) 2014-06-20 2015-12-23 The General Hospital Corporation Collagen targeted imaging probes
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN107624115B (zh) 2015-03-16 2021-10-26 加州理工学院 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法
EP3322716B1 (en) 2015-07-15 2025-02-12 California Institute of Technology Il-17f-specific capture agents and methods of using
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
EP3535278A4 (en) 2016-11-01 2020-06-24 Ohio State Innovation Foundation METHOD FOR IODING BIOMOLECULES
KR20190135500A (ko) * 2017-04-27 2019-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 개질된 mri 조영제 및 이의 용도
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2019075213A1 (en) * 2017-10-11 2019-04-18 Northwestern University HEPARIN CONJUGATED TO PEPTIDES BINDING TO COLLAGEN FOR TARGETING BIOLOGICAL AND SYNTHETIC FABRICS
CN108314695B (zh) * 2018-01-04 2020-06-16 南京邮电大学 一种异种双核金属配合物的制备及应用
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
WO2020093055A2 (en) 2018-11-02 2020-05-07 Indi Molecular, Inc. Peptide libraries with non-canonical amino acids
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US20200291391A1 (en) 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
EP3972646A4 (en) 2019-05-20 2023-06-14 Ohio State Innovation Foundation APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USE THEREOF
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
CN112891566A (zh) * 2019-12-04 2021-06-04 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 一种纳米材料及其制备方法和包含其的造影剂
EP4143227A2 (en) 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antibodies
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
CN120093699B (zh) * 2025-03-06 2025-11-14 浙江大学 用于定位并稳定动脉粥样硬化斑块的诊疗分子、纳米粒及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
AU8152887A (en) * 1986-10-17 1988-05-06 Cytogen Corporation Method for preparation of protein-chelator-metal ion compositions suitable for injection
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
US5171563A (en) 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
WO1991003200A1 (en) * 1989-08-28 1991-03-21 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
USH1312H (en) * 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
ES2140469T3 (es) * 1992-10-14 2000-03-01 Nycomed Imaging As Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes.
DE4341724A1 (de) 1993-12-03 1995-06-08 Schering Ag Halogenaryl-substituierte Metallkomplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
EP0731797B1 (en) * 1993-12-03 1999-09-08 BRACCO S.p.A. Paramagnetic chelates for nuclear magnetic resonance diagnosis
TW319763B (2) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19507822B4 (de) * 1995-02-21 2006-07-20 Schering Ag Substituierte DTPA-Monoamide der zentralen Carbonsäure und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5707605A (en) * 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents

Also Published As

Publication number Publication date
DE69729380D1 (de) 2004-07-08
US20040156785A1 (en) 2004-08-12
JP2000507577A (ja) 2000-06-20
JP2004210796A (ja) 2004-07-29
WO1997036619A3 (en) 1998-01-29
ES2217408T3 (es) 2004-11-01
CA2247620A1 (en) 1997-10-09
BR9708470A (pt) 1999-04-13
IL125895A (en) 2001-09-13
US20060275216A1 (en) 2006-12-07
NO319674B1 (no) 2005-09-05
US20020034476A1 (en) 2002-03-21
NO984543L (no) 1998-11-26
HK1016877A1 (en) 1999-11-12
ATE268187T1 (de) 2004-06-15
IS2059B (is) 2005-10-14
IS4833A (is) 1998-08-26
NZ331629A (en) 2000-04-28
NO984543D0 (no) 1998-09-29
KR20060025233A (ko) 2006-03-20
CN1108824C (zh) 2003-05-21
WO1997036619A2 (en) 1997-10-09
US7147837B2 (en) 2006-12-12
DE69729380T2 (de) 2005-07-14
DK0907379T3 (da) 2004-08-16
US6709646B2 (en) 2004-03-23
EP0907379B1 (en) 2004-06-02
IL125895A0 (en) 1999-04-11
CN1215341A (zh) 1999-04-28
EP0907379A2 (en) 1999-04-14
AU2544897A (en) 1997-10-22
AU726914B2 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
PT907379E (pt) Agentes de contraste bioactivados para imagiologia de diagnostico
NO20002380D0 (no) Forbindelser for før-døden diagnose av Alzheimers sykdom og in vivo billeddannelse, samt forhindring av amyloid deponering
EP0699051A4 (en) MACROMOLECULAR CONTRAST FOR IMAGE GENERATION BY MEANS OF MAGNETIC CORE RESONANCE
BR9607136A (pt) Agentes de contraste para formação de imagens para diagnóstico com retenção de sangue aumentada
EA200200220A1 (ru) Нацеливающие мультимерные визуализирующие агенты с механизмом мультилокусного связывания
ES2189873T3 (es) Agentes de imagen de resonancia magnetica para la deteccion de agentes fisiologicos.
NO991688L (no) Administrerbare sammensetninger og fremgangsmÕter til magnetisk resonansavbildning
EP0994352A3 (en) Contrast agent enhanced magnetic resonance imaging of myocardial tissue
EE05492B1 (et) Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral
NO20002517L (no) Magnetisk resonansavbildningsmidler for deteksjon av fysiologiske midler
WO2004064869A3 (en) Amyloid-binding, metal-chelating agents
NO20002115D0 (no) Magnetisk resonansavbilding for leveringen av terapeutiske midler
ATE310736T1 (de) Verbindungen zur bilddarstellung der alzheimer- krankenheit
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
BG104017A (en) The use of venous contrast matter for projection mammography
DK0759785T3 (da) Liposomsuspensioner som blodkontrastmidler
DE69732370D1 (de) Spinresonanz kontrastmittel für das blut
EP1048302A3 (en) Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
UA29125A (uk) Спосіб діагностики розсіяного склерозу
ITMI940414A0 (it) Procedimento per la coniugazione di proteine di interesse terapeutico o diagnostico